Laquinomod (Active Biotech/Teva) is filed at EMA for Multiple Sclerosis - 19-Jul-2012

Active Biotech/Teva has announced that the European Medicines Agency (EMA) has completed the validation process for the marketing authorization application of laquinimod for the treatment of relapsing-remitting Multiple Sclerosis.The submission is supported by a pooled analysis of data from the two global Phase III clinical trials in RRMS involving more than 2,400 patients treated for two years, the ALLEGRO and BRAVO trials.

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013